Citable filing context

ZBH filing events and research context

Server-rendered

ZBH's research view summarizes recent SEC filing context, starting with business from Feb 20, 2026.

ZBH filing events and research context
FiledItemContext
Feb 20, 2026businessThe provided text does not contain the Business Description (Item 1) of the company’s operations, products, or market strategy. Instead, the excerpt focuses on administrative disclosures, governance policies, and the index of exhibits for the 2026 Annual Report on Form 10-K. Key takeaways for a financial analyst from the provided documentation include the company’s recent corporate activity, specifically the January 2025 agreement and plan of merger with Paragon 28, Inc. The document also highlights the company’s ongoing capital structure management, evidenced by multiple supplemental indentures and revolving credit agreements executed through June 2025. Financial data provided is limited to a valuation and qualifying accounts schedule, which shows an increase in the allowance for doubtful accounts to $109.8 million and a rise in deferred tax asset valuation allowances to $573.0 million as of December 31, 2025. Additionally, the filing confirms the company’s continued separation from ZimVie Inc., following the 2022 distribution agreement. The provided text serves primarily as a reference for governance, executive compensation, and legal exhibits rather than a substantive overview of the company’s core business segments or competitive landscape.
Feb 20, 2026mdaZBH reported a 7.2% increase in 2025 net sales to $8.23 billion, driven by the acquisition of Paragon 28, market growth, and recovery from 2024 ERP-related fulfillment challenges. Despite top-line growth, net earnings fell to $705.1 million from $903.8 million, largely due to $170 million in inventory and instrument charges for discontinued product lines, acquisition-related costs for Paragon 28 and Monogram, and higher interest expenses. The S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) category was a standout performer, growing 15.2%, while Knees and Hips both grew 4.7%. Geographically, the U.S. and International markets saw similar growth rates of 7.3% and 7.0%, respectively. Management expects 2026 net sales growth of 2.5% to 4.5%, anticipating improved operating profit through fixed-cost leverage and the non-recurrence of 2025 inventory charges. Liquidity remains stable, with $591.9 million in cash and significant revolving credit availability. The company continues to prioritize capital allocation through dividends and share repurchases, recently authorizing a $1.5 billion buyback program. Key risks include ongoing pricing pressure from healthcare cost-containment efforts, potential volatility from go-to-market strategy shifts, and the integration of recent acquisitions, which currently carry lower operating margins than the core business.
Feb 20, 2026risk_factorsZimmer Biomet faces intense competition in orthopedics from Johnson & Johnson MedTech, Stryker Corporation, and Smith & Nephew plc, necessitating continuous innovation in its knees, hips, and S.E.T. products. Operational risks include potential disruptions in manufacturing, reliance on single-source suppliers for raw materials and sterilization, and challenges from a complex ERP system transition that previously impacted order fulfillment and sales in 2024. The company is also undergoing a multi-year U.S. sales force transformation from independent distributors to employees, which could lead to increased costs, reduced sales, and loss of key personnel. Global operations, comprising 42% of net sales, expose ZBH to currency fluctuations, trade barriers, and diverse regulatory environments, including volume-based procurement in China and "Buy local" initiatives that pressure pricing and demand. Substantial indebtedness of $7.5 billion increases debt service obligations and limits financial flexibility, exacerbated by rising interest rates. Compliance with evolving data privacy, cybersecurity, and healthcare fraud and abuse laws presents ongoing legal and financial risks, alongside potential product liability claims and the need to protect its extensive intellectual property portfolio of over 6,000 patents.

Source: SEC EDGAR filing text and events; period Feb 20, 2026; filed Feb 20, 2026.

Continue research

Keep researching ZBH

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →